The obesity drug market is no longer a rising tide lifting all boats. While Eli Lilly surges, Novo Nordisk faces a brutal 18% crash driven by shrinking market share and a transition to low-margin oral therapies. The introduction of federal price negotiations under the IRA has further compromised Novo's pricing power, signaling a permanent shift in the sector's power dynamics.

Global markets are fracturing as Google’s $185 billion AI spending spree spooked investors while software giants like Salesforce and Shopify face a massive valuation wipeout. This briefing explores whether the AI 'death knell' for software is a genuine shift or a historic buying opportunity in a market defined by panic and dislocation.

Beijing faces a daunting start to the year as its global influence suffers setbacks in Venezuela and Iran, imperiling crucial energy flows and strategic partnerships. Concurrently, a severe domestic obesity crisis in China forces aggressive state interventions and a rapid expansion of the GLP-1 drug market. This convergence of international pressure and internal challenge demands a critical reassessment of China's economic and geopolitical strategies, signaling a potentially turbulent yet transformative period ahead for the global economy.

The boundary between digital intelligence and physical health is dissolving as Nvidia's new 'Reuben' chips and Novo Nordisk's Wegovy pill hit the market simultaneously. While tech giants use 'reverse aqua-hires' to secure AI talent, the pharmaceutical world is removing the needle barrier to capture a hundred-million-strong patient base. This briefing explores how these parallel shifts in silicon and science are redefining global market leadership.